e-learning
resources
Vienna 2003
Monday 29.09.2003
Lung cancer: clinical presentation and prognostic factors
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Cytomegalovirus (CMV) damage of the lungs associated with pulmonary tumours: is it a fortuitousness or a rule?
V. I. Shakhgildian, O. A. Tishkevich, Y. G. Parkhomenko (Moscow, Russia)
Source:
Annual Congress 2003 - Lung cancer: clinical presentation and prognostic factors
Session:
Lung cancer: clinical presentation and prognostic factors
Session type:
Thematic Poster Session
Number:
1648
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
V. I. Shakhgildian, O. A. Tishkevich, Y. G. Parkhomenko (Moscow, Russia). Cytomegalovirus (CMV) damage of the lungs associated with pulmonary tumours: is it a fortuitousness or a rule?. Eur Respir J 2003; 22: Suppl. 45, 1648
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Epstein-Barr virus specific antibodies in patients with idiopathic pulmonary fibrosis and presence of EBV in respiratory tract: reactivation of infection?
Source: Eur Respir J 2005; 26: Suppl. 49, 333s
Year: 2005
Cytomegalovirus damage of the lungs among patients with HIV-infection
Source: Eur Respir J 2002; 20: Suppl. 38, 195s
Year: 2002
EBV and CMV as possible pathogens in patients presenting with interstitial lung disease
Source: Eur Respir J 2006; 28: Suppl. 50, 154s
Year: 2006
Cavitary lung masses in SLE patients: an unusual manifestation of CMV infection
Source: Eur Respir J 2004; 24: 182-184
Year: 2004
Cytomegalovirus infection in patients with lung tuberculosis
Source: International Congress 2018 – Tuberculosis comorbidities
Year: 2018
Pulmonary lymphoid hyperplasia (PLH) / lymphoid interstitial pneumonitis (LIP) complex in HIV-1 infected Brazilian children: associations and prognosis
Source: Annual Congress 2008 - Paediatric airway diseases - pathophysiology and monitoring
Year: 2008
Cytomegalovirus: an unrecognised potential contributor to cystic fibrosis disease progression?
Source: Eur Respir J, 53 (4) 1801727; 10.1183/13993003.01727-2018
Year: 2019
Effective prevention of human cytomegalovirus (HCMV) disease in lung transplant recipients (LTR) by pre-emptive therapy based on HCMV monitoring in blood and lung
Source: International Congress 2019 – Lung transplantation: from bench to bedside
Year: 2019
Cytomegalovirus infection in lung transplant patients: the role of prophylaxis and recipient-donor serotype matching
Source: Eur Respir J 2005; 26: Suppl. 49, 636s
Year: 2005
The frequency of cytomegalovirus infection detecting of patients with lung diseases
Source: Eur Respir J 2006; 28: Suppl. 50, 153s
Year: 2006
Lysozyme level and activity are decreased in the lungs of patients with idiopathic pulmonary fibrosis (IPF) and potentially contribute to increased susceptibility to pulmonary infection
Source: Annual Congress 2006 - Usefulness of broncoalveolar lavage (BAL) in interstitial lung diseases
Year: 2006
Immunity status of community acquired pneumonia (CAP) young patients according concomitant cytomegalovirus persistence (CMVP)
Source: International Congress 2019 – Host-microbe interactions in lung disease and exacerbations
Year: 2019
Non-infectious pulmonary complications in immunocompromised (IC) patients. Associated pulmonary and systemic inflammatory response
Source: Eur Respir J 2004; 24: Suppl. 48, 241s
Year: 2004
Pulmonary tuberculosis (TB) as a complication of idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis
Year: 2009
Human lung transplantation: cytomegaloviral and rhinoviral co-infection is a distinct risk for acute rejection
Source: Annual Congress 2009 - Human and experimental lung transplantation: novel findings
Year: 2009
Pulmonary diseases in primary immunodeficiency syndromes
Source: Respipedia Article
Year: 2017
Detection of herpes simplex virus type-1 (HSV-1) in lung tissue and bronchoalveolar lavage fluid (BALF) of patients with fibrotic idiopathic interstitial pneumonias (f-IIPs)
Source: Annual Congress 2009 - Pathogenesis of pulmonary fibrosis
Year: 2009
The role of cytomegalovirus infection in the course of the lung diseases in children
Source: Eur Respir J 2005; 26: Suppl. 49, 643s
Year: 2005
Herpes-simplex virus (HSV) in pulmonary tuberculosis (TB) with delayed response to treatment in patients from radio-nuclide contaminated areas (RNCA)
Source: Eur Respir J 2002; 20: Suppl. 38, 558s
Year: 2002
Risk of disease and latent infection among contacts of pulmonary and pleural tuberculosis in santarem (Portugal)
Source: Annual Congress 2009 - Tuberculosis contact screening
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept